AI Predicts Protein Structure & Binding – RamaOnHealthcare
- — A new artificial intelligence model promises to accelerate drug discovery.
- The breakthrough, achieved in just 20 seconds using a single GPU, builds upon the foundation of boltz-1.
- Boltz-1, the predecessor to this AI model, quickly became an industry standard for co-folding models after its release last fall.
MIT and Recursion have launched Boltz-2, an AI model poised to revolutionize drug finding by rapidly predicting protein structure and drug binding affinity. This cutting-edge technology, capable of delivering results in a mere 20 seconds using a single GPU, marks a significant leap forward in the request of artificial intelligence in biotechnology. Boltz-2 builds on the success of its predecessor, Boltz-1, and is accessible under an MIT license. This rapid advancement in AI-driven research could accelerate the growth of new treatments. For the latest news and breakthroughs in AI and healthcare, explore News Directory 3. Discover what’s next for pharmacological research with AI.
MIT Researchers Unveil Boltz-2 AI Model for Rapid Drug Revelation
Updated June 6, 2025
Cambridge, Mass. — A new artificial intelligence model promises to accelerate drug discovery. Researchers from MIT and Recursion announced the release of Boltz-2, an updated AI system capable of predicting protein structures and, crucially, binding affinity—the strength with which potential drugs attach to target proteins.
The breakthrough, achieved in just 20 seconds using a single GPU, builds upon the foundation of boltz-1. Boltz-2 was developed at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) under the direction of Regina Barzilay,in collaboration with Recursion scientists. The model is available for both commercial and non-commercial use under an MIT license.
Boltz-1, the predecessor to this AI model, quickly became an industry standard for co-folding models after its release last fall. Saro Passaro, an AI researcher, noted Boltz-2’s enhanced capabilities, stating it “doubling the performance of previous methods” in the realm of biotechnology and pharma-biotech.
What’s next
The release of boltz-2 marks a significant step forward in leveraging cognitive computing and AI for pharmaceutical research. Its speed and accuracy could dramatically shorten the drug growth timeline, perhaps leading to faster treatments for a variety of diseases.